Patents by Inventor Scott D. Schroeder

Scott D. Schroeder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
    Patent number: 12227520
    Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: February 18, 2025
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Lan Jiang, Jiayao Li, Michael L. Mitchell, Hyung-Jung Pyun, Scott D. Schroeder, Gregg M. Schwarzwalder, Nathan D. Shapiro, Devleena M. Shivakumar, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20250049780
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: July 12, 2024
    Publication date: February 13, 2025
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20250042915
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: June 14, 2024
    Publication date: February 6, 2025
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • GLP-1R modulating compounds
    Patent number: 12180197
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: December 31, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, Scott D. Schroeder, Nathan D. Shapiro, Suzanne M. Szewczyk, James G. Taylor, Nathan E. Wright, Sheila M. Zipfel
  • THERAPEUTIC COMPOUNDS
    Publication number: 20240376077
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: April 11, 2024
    Publication date: November 14, 2024
    Inventors: Michael Graupe, Steven J. Henry, John O. Link, Charles William Rowe, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • CD73 compounds
    Patent number: 12110294
    Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 8, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
  • SARS-COV2 main protease inhibitors
    Patent number: 12091420
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Grant
    Filed: October 3, 2023
    Date of Patent: September 17, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • Capsid inhibitors for the treatment of HIV
    Patent number: 12077537
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
    Type: Grant
    Filed: February 15, 2023
    Date of Patent: September 3, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Chienhung Chou, Scott E. Lazerwith, John O. Link, Scott D. Schroeder, Winston C. Tse, Jennifer R. Zhang
  • Thienopyrrole compounds
    Patent number: 12070455
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Grant
    Filed: September 8, 2022
    Date of Patent: August 27, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Yasamin Moazami, Scott D. Schroeder, Daniel G. Shore
  • COT MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20240254137
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Application
    Filed: December 11, 2023
    Publication date: August 1, 2024
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240239807
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: August 4, 2023
    Publication date: July 18, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • THIENOPYRROLE COMPOUNDS
    Publication number: 20240217990
    Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
    Type: Application
    Filed: February 8, 2022
    Publication date: July 4, 2024
    Inventors: Stephen E. Ammann, Eda Y. Canales, Weng K. Chang, Julian A. Codelli, Lan Jiang, Henok H. Kinfe, Scott E. Lazerwith, Michael L. Mitchell, Scott D. Schroeder, Daniel G. Shore
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20240199589
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: October 27, 2023
    Publication date: June 20, 2024
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Therapeutic compounds
    Patent number: 11993583
    Abstract: The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: May 28, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael Graupe, John O. Link, Roland D. Saito, Scott D. Schroeder, Dimitrios Stefanidis, Winston C. Tse, Jennifer R. Zhang
  • SARS-COV2 MAIN PROTEASE INHIBITORS
    Publication number: 20240116946
    Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 11, 2024
    Inventors: Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Scott E. Lazerwith, Jessica L. McKinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
  • THERAPEUTIC COMPOUNDS
    Publication number: 20240067629
    Abstract: The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.
    Type: Application
    Filed: July 18, 2023
    Publication date: February 29, 2024
    Inventors: Gediminas Brizgys, Eda Canales, Chienhung Chou, Michael Graupe, Jiayao Li, Roland D. Saito, Scott D. Schroeder, Winston C. Tse, Qiaoyin Wu, Jennifer R. Zhang
  • Cot modulators and methods of use thereof
    Patent number: 11905299
    Abstract: The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventors: Elizabeth M. Bacon, Gayatri Balan, Chien-Hung Chou, Christopher T. Clark, Jeromy J. Cottell, Musong Kim, Thorsten A. Kirschberg, John O. Link, Gary Phillips, Scott D. Schroeder, Neil H. Squires, Kirk L. Stevens, James G. Taylor, William J. Watkins, Nathan E. Wright, Sheila M. Zipfel
  • CD73 COMPOUNDS
    Publication number: 20240043427
    Abstract: The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.
    Type: Application
    Filed: April 29, 2021
    Publication date: February 8, 2024
    Inventors: Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
  • GLP-1R modulating compounds
    Patent number: 11858918
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 2, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • GLP-1R MODULATING COMPOUNDS
    Publication number: 20230391747
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 7, 2023
    Inventors: Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Michael Graupe, Chao-I Hung, Kavoos Kolahdouzan, Scott D. Schroeder, Nathan D. Shapiro, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel